The U.S. Department of Veterans Affairs is launching a clinical trial to evaluate whether semaglutide, a GLP-1 receptor agonist used to treat diabetes, can treat alcohol use disorder among veterans, according to a July 30 news release. The trial comes…
GLP-1s
Cigna pulled back GLP-1 weight-loss coverage for its own employees July 1. Now it says its clients have been doing the same. On a July 30 earnings call, Cigna President and CEO Brian Evanko said Evernorth Health Services has seen…
Demand for GLP-1 weight loss drugs and other temperature-sensitive therapies is driving shipping and logistics companies to expand their healthcare operations, according to a July 25 CNBC report. UPS, FedEx, DHL and C.H. Robinson are investing in temperature-controlled storage, cold-chain…
Patient safety groups are warning that an FDA advisory committee’s decision to recommend expanding compounding access to wellness peptides came without the safety and efficacy evidence needed to justify it. The FDA’s Pharmacy Compounding Advisory Committee voted during its July…
A new fracture-risk finding is complicating the bone-safety picture for GLP-1s, alongside fresh data on hair loss, sick leave and adherence. Here are six recent findings to know:
Advertisement
The FDA’s Pharmacy Compounding Advisory Committee wrapped a two-day meeting July 24, ultimately recommending six of the seven peptides under review — BPC-157, KPV, TB-500, MOTs-C, epitalon and Semax — for inclusion on the agency’s Section 503A Bulk Drug Substances…
GLP-1 receptor agonists carry a higher risk of hair loss than other diabetes medications, according to a study published July 22 in The BMJ. Researchers at Philadelphia-based Penn Medicine used EHR data to compare adults with Type 2 diabetes who…
A research letter published online July 20 in JAMA Pediatrics examined obesity treatment trends among adolescents and young adults between May 2022 and January 2026. Here are four findings to know: The shift builds on trends already showing up in…
Some compounding pharmacies are sidestepping the FDA’s ban on copying approved GLP-1s by adding a vitamin or supplement to their formulations, according to a report published July 17 in JAMA Health Forum. The finding is a sign that the legal…
GLP-1 medications are linked to a 17.3% drop in long-term sickness leave over four years, according to a working paper published in July by the National Bureau of Economic Research. Researchers compared 7,011 patients who started Ozempic during the drug’s…